Graham Capital Management L.P. Makes New Investment in ADMA Biologics, Inc. (NASDAQ:ADMA)

Graham Capital Management L.P. acquired a new stake in ADMA Biologics, Inc. (NASDAQ:ADMA) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 11,726 shares of the biotechnology company’s stock, valued at approximately $201,000.

A number of other institutional investors and hedge funds have also made changes to their positions in ADMA. Barclays PLC raised its holdings in shares of ADMA Biologics by 192.2% in the 3rd quarter. Barclays PLC now owns 528,629 shares of the biotechnology company’s stock valued at $10,567,000 after purchasing an additional 347,692 shares in the last quarter. Perpetual Ltd acquired a new stake in ADMA Biologics in the fourth quarter valued at $62,300,000. Nisa Investment Advisors LLC lifted its holdings in ADMA Biologics by 133.9% during the 4th quarter. Nisa Investment Advisors LLC now owns 7,378 shares of the biotechnology company’s stock worth $127,000 after buying an additional 4,224 shares during the last quarter. Veracity Capital LLC boosted its position in shares of ADMA Biologics by 117.0% during the 4th quarter. Veracity Capital LLC now owns 46,415 shares of the biotechnology company’s stock worth $796,000 after acquiring an additional 25,030 shares in the last quarter. Finally, KBC Group NV boosted its position in shares of ADMA Biologics by 53.6% during the 4th quarter. KBC Group NV now owns 10,063 shares of the biotechnology company’s stock worth $173,000 after acquiring an additional 3,513 shares in the last quarter. 75.68% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on ADMA shares. StockNews.com lowered ADMA Biologics from a “hold” rating to a “sell” rating in a research report on Friday, May 9th. Raymond James raised their price objective on shares of ADMA Biologics from $25.00 to $32.00 and gave the stock a “strong-buy” rating in a report on Thursday, May 8th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $25.00 price objective on shares of ADMA Biologics in a research report on Tuesday, March 4th. One investment analyst has rated the stock with a sell rating, three have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $24.25.

ADMA Biologics Stock Up 2.6%

Shares of NASDAQ ADMA opened at $19.69 on Monday. The business has a 50-day moving average price of $20.49 and a 200 day moving average price of $18.86. The stock has a market cap of $4.70 billion, a PE ratio of 70.32 and a beta of 0.57. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. ADMA Biologics, Inc. has a 52-week low of $9.22 and a 52-week high of $25.67.

ADMA Biologics (NASDAQ:ADMA) last announced its earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.16 by ($0.02). ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. The business had revenue of $114.80 million for the quarter, compared to analysts’ expectations of $116.40 million. During the same quarter last year, the business posted $0.08 earnings per share. The business’s revenue was up 40.2% on a year-over-year basis. Equities research analysts forecast that ADMA Biologics, Inc. will post 0.51 earnings per share for the current year.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.